The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders
Abstract
Four groups recently reported the existence of an activating mutation of JAK2 in many patients with one of the classic myeloproliferative disorders (MPDs).[1][1]-[4][2] Mutant Janus kinase 2 (JAK2) has increased kinase activity, renders BaF3 cells cytokine independent, and produces erythrocytosis in
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Activation of JAK2 caused by the V617F mutation leads to constitutive activation of STAT3 and is associated with reduced survival in idiopathic myelofibrosis.
“Activation of JAK2 caused by this mutation leads to constitutive activation of STAT3 and is associated with reduced survival in idiopathic myelofibrosis.54,55”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [53]
Cited by
Sorted by citations
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123 · see citing works
Self-citationCritical analysis of the potential for targeting STAT3 in human malignancy
Grandis, J., & Peyser (2013) · OncoTargets and Therapy · doi:10.2147/ott.s47903 · Cited by 24 · see citing works
“Similar results have been found for other kinase domain mutations, including the wellstudied JAK2 mutation V617F, which is primarily found in myeloproliferative disorders.(52,53) Activation of JAK2 caused by this mutation leads to constitutive activation of STAT3 and is associated with reduced survival in idiopathic m…”
- Authors
- Scott, L. M., Campbell, P. J., Baxter, E. J., Todd, T., Stephens, P., Edkins, S., Wooster, R., Stratton, M. R., Futreal, P. A., & Green, A. R.
- Affiliations
- University of Cambridge (GB)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-10-15
- Volume
- 106
- Issue
- 8
- Pages
- 2920-2921
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2017410022
- Cited by
- 158
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2021: 5 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 8 · 2015: 4 · 2014: 4 · 2013: 11 · 2012: 14
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust (088340)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- JAK2 V617F mutation, myeloproliferative neoplasms, myeloid neoplasms, cancer, erythrocytosis, kinase activity
- MeSH terms
- Cells, Cultured, Genetic Testing, Humans, Multiple Myeloma, Mutation, Myeloproliferative Disorders, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Valine, Janus Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
